OASIS-4 in Focus: Lead Investigator Reviews Trial Design
June 20th 2025A panelist highlights that at ASCO 2025, a landmark phase 3 trial showed a new treatment significantly reduced moderate-to-severe hot flashes in patients with breast cancer receiving endocrine therapy, with rapid and sustained symptom relief and high patient continuation rates over 2 years.
How New Pathways Are Easing Vasomotor Symptoms in Breast Cancer Care
June 20th 2025A panelist explains that although hormone replacement therapy is contraindicated in patients with breast cancer due to recurrence risks, new nonhormonal treatments targeting neurokinin receptors in the brain offer promising relief for vasomotor symptoms without interfering with endocrine therapy.
Navigating Vasomotor Symptoms From Endocrine Therapy in Breast Cancer Treatment
June 13th 2025A panelist notes that although chemotherapy’s adverse effects are intense but short-lived, endocrine therapy for hormone receptor–positive breast cancer involves persistent symptoms over several years, making symptom management essential for patient adherence and quality of life.
Lead Investigator Insights on Adjuvant Endocrine Therapy Landscape
June 13th 2025A panelist discusses how endocrine therapy remains the cornerstone of treatment for hormone receptor–positive, HER2-negative breast cancer, emphasizing its role in reducing relapse risk and mortality while highlighting the importance of tolerability and individualized care across the subtype’s heterogeneous presentations.
Negative pressure wound therapy reduces c-section infections and costs
May 20th 2025Tia Welsh, MD, MPH, FACOG, shares new evidence showing that single-use negative pressure wound therapy at -80 mmHg lowers cesarean-section infection rates and healthcare costs more effectively than traditional -125 mmHg therapy.